+629.1%
MRNA vs GSK
+84.4%
+544.7%
-95.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | +0.2% | -3.5% | -3.5% |
| 7D | -10.1% | -3.6% | -6.5% | -8.2% |
| 30D | +126.7% | -5.9% | +132.7% | +138.2% |
| 3M | +184.1% | -4.3% | +188.4% | +195.9% |
| 6M | +143.3% | -10.8% | +154.1% | +160.4% |
| YTD | +359.9% | +1.8% | +358.1% | +365.1% |
| 1Y | +454.2% | +23.5% | +430.7% | +417.5% |
| 3Y | +26.0% | +49.5% | -23.6% | +9.3% |
| 5Y | -70.3% | +49.7% | -119.9% | -74.5% |
| All | +629.1% | +84.4% | +544.7% | +386.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling